Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
Status:
Completed
Trial end date:
2021-09-18
Target enrollment:
Participant gender:
Summary
In this translational research proposal, based on our formulation, we seek to confirm and
expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid
agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring
cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in
these patients and, thereby, provide evidence in support of the role of cannabis as a
"self-medication" agent for them.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
Columbia University Harvard Medical School Harvard Medical School (HMS and HSDM) Massachusetts General Hospital Massachusetts Institute of Technology Nathan Kline Institute for Psychiatric Research National Institute on Drug Abuse (NIDA) University of Vermont